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The Rip1Tag2 transgenic mouse model of pancreatic b-cell car-
cinogenesis has been instrumental in identifying several hall-
marks of cancer, including tumor cell evasion from apoptosis,
tumor angiogenesis and tumor invasion. Moreover, Rip1Tag2
mice have been helpful in the development and testing of innova-
tive cancer therapies and tumor imaging protocols. However,
based on tumor localization in the mouse, primary tumor growth
and metastatic dissemination cannot be easily monitored in a lon-
gitudinal axis by non-invasive and low-technology approaches.
Here, we report the generation of a new transgenic mouse line
as a versatile tool to study b-cell carcinogenesis. Transgenic
expression of a bicistronic messenger RNA encoding simian virus
large T antigen and firefly luciferase in pancreatic b-cells recapit-
ulates insulinoma development in a reproducible multistage
process. In the mouse line called RipTag-IRES-Luciferase line
(RTL) 1, the b-cell-specific expression of luciferase allows the non-
invasive monitoring of primary tumor growth over time in vivo and
the detection and quantification of disseminated tumor cells and
micrometastases in distant organs ex vivo. When crossed to mouse
lines in which the expression of cancer ‘modifier’ genes has been
manipulated, tumor initiation and tumor progression are similarly
affected as previously reported for Rip1Tag2 mice, indicating a ro-
bust tumor progression pathway shared between the two different
transgenic mouse lines. Together, the data indicate that the RTL1
mouse line will be of great value to study anti-tumoral therapeutic
approaches as well as to define the functional roles of cancer- and
metastasis-related genes when crossed to appropriate transgenic or
gene-targeted mouse lines.
Introduction
First transgenic mouse models of cancer have been established in the
mid-1980s by the tissue-specific transgenic expression of oncogenes
in mice resulting in the development of various cancer types (1). In the
meantime, a plethora of murine cancer models has been established,
and the range of transgenic tumor models has been expanded by
models in which tumor suppressor genes have been inactivated by
targeted recombination (knockout mice) or by chemical, pharmaco-
logical and hormonal induction protocols of cancer.
One of the first transgenic ‘oncomouse’ has been the Rip1Tag2
mouse line, expressing SV40 large T antigen (Tag) under the control
of the rat insulin promoter (Rip) and recapitulating tumorigenesis of
the pancreatic b-cells in the islets of Langerhans (2). This mouse
model has been widely used as a model of multistage tumorigenesis
in cancer research and, together with others, has substantially con-
tributed to the concept summarized as ‘hallmarks of cancer’ (3).
Notably, the Rip1Tag2 transgenic mouse model has been instrumental
in visualizing the onset of tumor angiogenesis (the ‘angiogenic
switch’), a highly regulated process that is mainly governed by the
expression of pro-angiogenic growth factors, including vascular en-
dothelial growth factor A (VEGF)-A (4–6). The gain of survival sig-
naling to overcome apoptosis during tumor development has been
demonstrated by the upregulated expression of insulin-like growth
factor II (IGF-II) during Rip1Tag2 tumorigenesis (7). Finally, Rip1-
Tag2 mice have been instrumental to demonstrate the critical role
of cell adhesion molecules, such as E-cadherin, during malignant
tumor progression and metastasis (8). Another critical feature of
cancer development is the interaction of a tumor with its microen-
vironment and inflammatory cells that promote tumor growth, an-
giogenesis and invasion and help the tumor to evade immune
surveillance (reviewed in ref. 9). Also here, Rip1Tag2 mice have
been employed to define the critical role of bone marrow-derived
cells, such as neutrophils, in supplying matrix metalloproteinase 9,
which can activate matrix-sequestered VEGF-A and thus tumor
angiogenesis (6,10). Finally, Rip1Tag2 mice have been employed
to develop novel radiopeptide-mediated imaging of insulinoma,
currently being tested in the clinics (11).
Despite its established usefulness for basic and translational cancer
research, the Rip1Tag2 model has also its limitations. Islets of Lang-
erhans and the tumors derived thereof are buried deep in the mouse
body, rendering it difficult to monitor tumor growth in living mice in
longitudinal analyses. Even though many preclinical studies have
been undertaken with Rip1Tag2 mice (12–18), the necessity to set
a defined end point due to unknown tumor growth diminishes the
flexibility in the analysis of this cancer model. Another drawback of
the Rip1Tag2 mouse model is its transgene integration site. The close
proximity to the glucagon gene causes aberrant expression of T anti-
gen in gastrointestinal L cells, occasionally giving rise to intestinal
neuroendocrine carcinoids and hampering the analysis of b-cell
tumorigenesis (19,20).
Here, we report the generation and characterization of an improved
version of the Rip1Tag2 mouse model in which firefly luciferase is
expressed in addition to SV40 T antigen specifically in the pancreatic
b-cells [RipTag-IRES-Luciferase (RTL) 1]. In these mice, tumor
growth can be monitored non-invasively by bioluminescence analysis,
and metastatic events can be easily monitored by luciferase activity in
distant organs in vivo and ex vivo. Moreover, in RTL1 mice, expres-
sion of T antigen is highly restricted to pancreatic b-cells, and no other
tumor type occurs. Finally, the reproducible recapitulation of all dis-
tinct tumor stages observed in human cancer, including the onset of
angiogenesis and occasional lymph node and distant metastasis, make
it a suitable model for genetic and pharmacological experimentation.
Materials and methods
Generation of RipTag-IRES-Luciferase transgenic mice
A DNA fragment containing the rat insulin promoter 1 regulatory region, the
SV40 early region, followed by an internal ribosomal entry site (IRES), the
firefly luciferase coding region and the SV40 early polyadenylation signal was
generated as described in supplementary Methods (available at Carcinogenesis
Online). The linearized transgene construct was microinjected into pronuclei
of fertilized FVB/N eggs according to standard techniques (21). Genomic
polymerase chain reaction (PCR) identified three founder lines designated
RTL1, 2 and 3. All other transgenic mouse lines have been previously reported
(22–26). All experiments involving mice were performed in accordance with
the guidelines of the Swiss Federal Veterinary Office and the regulations of the
Cantonal Veterinary Office of Basel-Stadt.
In vivo bioluminescence
Prior to measurement, mice were shaved in the peritoneal region and injected
intraperitoneally with D-luciferin potassium salt (Gold BioTechnology,
St Louis, MO) dissolved in sterile phosphate-buffered serum at 15 mg/ml with
Abbreviations: BrdU, bromodeoxyuridine; IGF-II, insulin-like growth factor
II; IGF1R, insulin-like growth factor receptor 1; LYVE-1, lymphatic vessel
endothelial hyaluronan receptor 1; MDSC, myeloid-derived suppressor cells;
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a luciferin dose of 150 mg/kg body weight. Five minutes after luciferin in-
jection, mice were anaesthetized by inhalation of 3% isoflurane (Provet AG,
Lyssach, Switzerland) and placed in the dark chamber of the ‘NightOWL II LB
983’ imaging system (Berthold Technologies, Bad Wildbad, Germany). For
quantification experiments with multiple rounds of monitoring, timing of in-
jection, anesthesia and camera setting were standardized and kept constant
throughout the experiment. Typical acquisition times were between 1 and
5 min with maximal binning. For quantification of light intensities in time
course experiments, a constant analysis gate was defined and individual tumor
photon counts were determined by centering the gate on the highest signal
intensity for each time point.
Fluorescence-activated cell sorting analysis
Peripheral blood was drawn directly by heart puncture of CO2 killed mice and
transferred to ethylenediaminetetraacetic acid anti-coagulated collection tubes
(Sarstedt, Sevelen, Switzerland). For details of the fluorescence-activated
cell sorting analysis, see supplementary Methods (available at Carcinogenesis
Online).
Quantitative real-time reverse transcription–PCR
Total RNA from tumors or total pancreas was prepared using TRI Reagent
(Sigma, Buchs, Switzerland) and reverse transcribed with random hexamer
primers using moloney murine leukemia virus reverse transcriptase (Sigma).
Complementary DNA was quantified on an ABI Prism 7000 light cycler
(Applied Biosystems, Zug, Switzerland) using SYBR green PCR MasterMix
(Fermentas) using the primers described in supplementary Table S2 (available
at Carcinogenesis Online). Ct values were normalized against ribosomal
protein L19 (RPL19) and fold induction was calculated as 2DDCt
Quantification of luciferase activity
Organs and tumors were homogenized into precooled Reporter Lysis Buffer
(Promega, Duebendorf, Switzerland). Samples were cleared by cetrifuga-
tion and supernatants stored at 20C until further analysis. For quantification,
10 ll of lysate was mixed with 50 ll of Luciferase Assay Reagent (Promega) and
luminescence measured on a Centro LB 960 luminometer (Berthold Technolo-
gies). Liver and lung lysates were found to have a high quenching activity and
were used in a 1:5 dilution.
Histology and immunostaining
See supplementary Methods available at Carcinogenesis Online.
Statistical evaluation
All statistical tests were performed using GraphPad Prism 4.0c for Mac. Data
were first tested for normality and when normality was fulfilled, unpaired two-
tailed Student’s t-test was applied. For non-Gaussian data, Mann–Whitney
non-parametric U-test was performed. Survival data were analyzed by log-rank
test. P values ,0.05 were considered statistically significant.
Results
Generation of transgenic RTL mice
An expression cassette was generated in which SV40 large T antigen
and firefly luciferase are expressed in a bicistronic manner under the
control of the rat insulin promoter specifically in b-cells of the islets of
Langerhans (supplementary Figure S1A is available at Carcinogene-
sis Online). The linearized plasmid construct was then used to gen-
erate transgenic mice in the FVB/N genetic background. Three
founder lines, termed RTL1, 2 and 3, developed fatal insulinomas.
In lines RTL2 and 3, only males developed tumors (within 25 weeks),
even though the transgene had not integrated in the Y chromosome.
The levels of messenger RNA (mRNA) encoding for large T antigen
in islets of Langerhans from young non-tumor-bearing mice were
found 12- to 20-fold lower in RTL2 and 3 mice as compared with
RTL1 mice (data not shown).
In vivo bioluminescence signals were aberrant in lines RTL2 and 3,
whereas in the RTL1 line, tumors as small as 2 mm could be detected
at the expected site located in the higher peritoneal region
(Figure 1A). Tissue-specific expression of the transgene was deter-
mined by analyzing luciferase activity in organ lysates from 6- to
8-week-old RTL mice, when the mice were still tumor free. Lucifer-
ase activity levels were very low in most of the organs analyzed
(supplementary Figure S1B is available at Carcinogenesis online).
Testis and fat tissue lysates were positive in all mouse lines, indicating
baseline activity of the rat insulin promoter in this organ. Preputial
gland was positive in lines RTL2 and 3, and males of the line RTL3
showed aberrant luciferase expression in the skin. However, besides
tumors of pancreatic b-cells, no other tumor type was detected in the
three transgenic lines. Based on its robust and reproducible transgene
expression and tumor development, line RTL1 was selected for fur-
ther experimentation.
We next determined the transgene integration site in the RTL1 line
by linker-mediated PCR. The single integration site was localized
distal to the H4 region of chromosome 3, 100 and 500 kb apart from
the next annotated genes (supplementary Figure S1C is available at
Carcinogenesis Online). Quantitative PCR on genomic DNA revealed
that RTL1 mice carried 40 transgene copies per heterozygous
genome as compared with five copies in Rip1Tag2 mice (data not
shown). Mice homozygous for the RTL1 transgene did not show
any abnormalities, indicating negligible distortion of the genomic
locus (supplementary Figure S1D is available at Carcinogenesis
Online). Nevertheless, all the experiments reported here have been
performed with heterozygous RTL1 mice.
Lysates from RTL1 tumors exhibited very high luciferase expres-
sion levels (supplementary Figure S2A is available at Carcinogenesis
Online), about three to five orders of magnitude above the levels
detected in liver and lung, two potential target organs of insulinoma
metastasis. The variability in luciferase activities found between in-
dividual tumors might reflect the different levels of insulin expression
in insulinomas (Figure 4C) as well as varying relative proportions of
tumor cells constituting the tumor mass. Two cell lines derived from
tumors of RTL1 mice showed significantly higher levels of luciferase
activity than primary tumors (supplementary Figure 2A is available at
Carcinogenesis Online). One of these cell lines homogeneously
expressed T antigen and insulin (Figure 1B) and denoted the upper
limit of luciferase expression in the RTL1 system.
Tumors of RTL1 mice expressed about four times more T antigen
transcript as compared with tumors of Rip1Tag2 mice, a finding con-
firmed by immunoblotting analysis (Figure 1C, data not shown). In
contrast, T antigen mRNA levels were 2-fold higher in total pancreata
from newborn Rip1Tag2 mice as compared with newborn RTL1 mice.
Kinetics of tumor development
In our laboratory, Rip1Tag2 mice are usually bred in the C57Bl/6
background, and the average life span of these mice is 12.6 weeks.
Average tumor volumes of Rip1Tag2 mice at 12 weeks are 36 mm3.
In contrast, RTL1 mice in FVB/N background have a median survival
of 20.7 weeks, with a median survival of 19.4 weeks for female and
22.0 weeks for male mice (supplementary Figure S2B is available at
Carcinogenesis Online). At age 18–20 weeks, tumor volumes of
RTL1 female versus male mice did not significantly differ, with an
average tumor volume of 99 ± 29 mm3 and 65 ± 12 mm3 for females
and males, respectively [Figure 1D, mean ± standard error of the mean
(SEM)]. However, at age 21–22 weeks, average tumor size of females
was lower (37 ± 11 mm3) as compared with males (233 ± 33 mm3)
(Figure 1D). At this age, males have a significantly higher survival
rate than females, indicating that females alive at this age have a de-
layed tumor progression, whereas males can live under higher tumor
burden. The kinetics of tumor development in RTL1 mice appeared to
be unchanged in a pure FVB/N background versus C57/FVB mixed
background (supplementary Figure S2B is available at Carcinogene-
sis Online), indicating a certain independence of RTL1 tumorigenesis
from the genetic background.
To assess how RTL1 tumor development is affected by the activity
of factors known to modify tumor progression, RTL1 mice were
crossed to mice expressing tumor ‘modifier’ genes in pancreatic
b-cells under the control of the rat insulin promoter. These mouse
lines have been previously characterized, also by intercrossing them
with the Rip1Tag2 tumor model. For example, transgenic expression
of VEGF-A accelerates tumor growth in Rip1Tag2 mice without
affecting metastases (22), whereas VEGF-C and VEGF-D promote
tumor lymphangiogenesis and lymph node metastases (23,25).
Insulin-like growth factor receptor 1 (IGF1R) over-expression
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promotes tumor growth and progression in Rip1Tag2 mice (24), and
neural cell adhesion molecule (NCAM) deficiency causes lymph node
metastases by decreasing tumor–extracellular matrix adhesion and
increasing tumor lymphangiogenesis (26,27).
As previously reported for Rip1Tag2 mice, composite trans-
genic mice of RTL1;RipVEGF-C, RTL1;RipVEGF-D and
RTL1;NCAMþ/ genotype, no difference in survival was observed.
In contrast, as also reported before for Rip1Tag2 mice, transgenic
co-expression of VEGF-A or IGF1R under the Rip promoter
caused a drastic highly significant survival reduction in RTL1;Rip-
VEGF-A and RTL1;RipIGF1R mice (supplementary Figure 2C and
D is available at Carcinogenesis Online).
No significant changes in tumor volume or incidence were seen in
RTL1 mice crossed to RipVEGF-C, RipVEGF-D or NCAMþ/ com-
posite mice (Figure 1E, supplementary Table S1, available at Carci-
nogenesis Online), a result comparable with previously published data
on RipVEGF-C, RipVEGF-D and NCAMþ/ in Rip1Tag2 mice. In
contrast, RTL1;RipIGF1R had larger and twice as many macroscopic
tumors than RTL1 mice (Figure 1E, supplementary Table S1, avail-
able at Carcinogenesis Online), even though they were analyzed at
only 9–11 weeks of age (versus 18–20 weeks in single-transgenic
RTL1 mice), highlighting the role of IGF1R as a tumor progression
factor. Curiously, RTL1;RipVEGF-A double-transgenic mice had sig-
nificantly smaller tumors than RTL1 mice at time of death (Figure 1E,
supplementary Table S1, available at Carcinogenesis Online). Tumor
lysates derived from these composite mice did not exhibit signifi-
cantly different luciferase activities, indicating that the expression
of modifier genes had no significant impact on transgene expression
(supplementary Figure S2A, available at Carcinogenesis Online).
Bioluminescence quantification of tumor growth in vivo
As described above, luciferase activities varied largely between dif-
ferent tumors of RTL1 mice. Bearing this in mind, tumor growth was
monitored in individual mice over a period of 4 weeks by in vivo
Fig. 1. In vivo bioluminescence and tumor detection. (A) In vivo luciferase bioluminescence analysis of transgenic mouse lines RTL1, 2 and 3. (B) Cell lines
derived from RTL1 tumors show homogeneous insulin and SV40 large T antigen expression as determined by immunofluorescent staining; scale bar: 20 lm.
(C) T antigen mRNA expression in total pancreas and tumors of newborn and adult Rip1Tag2 and RTL1 mice, respectively, as determined by quantitative reverse
transcription–PCR. (D) RTL1 males and females exhibit similar tumor volumes before 20 weeks of age, whereas at the age of 22 weeks, male mice develop larger
tumors. (E) Tumor volumes in single-transgenic RTL1 and in composite double-transgenic RTL1;RipIGF1R, RTL1;RipVEGF-C, RTL1;RipVEGF-D and
RTL1;NCAMþ/ mice. Shown are individual values with means ± SEMs. For statistical test see supplementary Table S1 (available at Carcinogenesis Online).
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bioluminescence once or twice weekly. Signal intensity was
maximal 10 min after D-luciferin injection and stayed at plateau
levels for 20–30 min (data not shown). As tumors were localized at
various sites and depths within the pancreas, absolute luciferase in-
tensities and thus tumor sizes could not be directly compared between
different mice. Yet, for individual mice, an increase in luciferase
activity and thus tumor growth could be monitored over time (Figure
2A). Analysis of a large cohort of mice revealed a 3-fold increase
in normalized signal intensity over the analysis period of 4 weeks
(Figure 2B).
Tumor progression
Hyperplastic islets and dysplastic angiogenic islets were detected in
RTL1 mice as early as 7 weeks of age, as visualized by bromodeox-
yuridine (BrdU) incorporation in hyperplastic but not in normal islets
and by increasing vessel densities and hemorrhages in angiogenic
islets. Beginning at 10 weeks of age, macroscopic tumors could be
detected. The low abundance of macroscopic tumors in RTL1 mice
detected by bioluminescence was confirmed by histopathological
analysis. According to the previously reported classification of Rip1-
Tag2 tumors (8), we classified the stages of tumor development in
RTL1 mice into the following categories: normal islets, hyperplastic
islets, angiogenic islets, adenoma and carcinomas of grade 1 (micro-
invasive), grade 2 (fully invasive) and grade 3 (anaplastic) (Figure 3A;
data not shown). In grade 2 tumors, detached tumor cell clusters were
often detected within the tumor (Figure 3B) and in blood vessels
within the exocrine pancreas (Figure 3C), indicating tumor disaggre-
gation and tumor cell dissemination. In general, pancreata of Rip1-
Tag2 mice showed a higher abundance of tumors as compared with
RTL1 mice (Figure 3D). Per pancreatic tissue section from RTL1
mice was analyzed at the age of 18–20 weeks, in average 5.5 ± 1.8
normal/hyperplasic islets, 5.5 ± 1.6 adenoma and 1.6 ± 0.3 carcinoma
were detectable (mean per mouse ± SEM, 6 mice, 76 counted lesions).
BrdU injection 2 h before killing and staining for incorporated BrdU
revealed a proliferation rate of 10.1 ± 0.7% of all tumor-constituting
cells (mean of microscopic fields ± SEM; 3 mice, 12 tumors, 27
microscopic fields). TdT-mediated dUTP-biotin nick end labeling
staining revealed 1.05 ± 0.08% apoptotic cells within tumors (mean
of microscopic fields ± SEM; 4 mice, 9 tumors, 25 microscopic
fields). Tumor hypoxia was analyzed by immunohistochemical
staining for the hypoxia-inducible factor 1 alpha target gene carbonic
anhydrase IX (Ca-IX; reviewed in ref. 28). Ca-IX staining was found
absent or very low in tumors of both Rip1Tag2 and RTL1 mice (sup-
plementary Figure S3A, available at Carcinogenesis Online), indicat-
ing low tumor hypoxia in both mouse models. Interestingly, in
Rip1Tag2 but not in RTL1 mice, the tumor-surrounding exocrine
tissue upregulated Ca-IX expression in the vicinity of the invasion
fronts of carcinoma.
Immunohistochemical staining of tumor sections with antibodies
against CD31 revealed that larger tumors were less vascularized to-
ward the tumor center as compared with the outer rims (Figure 4A).
NG2, a proteoglycan indicative for pericytes, strictly colocalized with
blood vessels in the tumor periphery (Figure 4A). In contrast, al-
though widely devoid of CD31-positive vessels, central tumor regions
contained NG2-positive pericytes, possibly as remnants of previously
intact tumor vasculature.
We next assessed the expression of E-cadherin, an epithelial marker
expressed in b-cells of Langerhans islets and reduced in its expression
during the transition from adenoma to carcinoma during Rip1Tag2
tumorigenesis (26). In RTL1 mice, E-cadherin expression was
found to be retained in hyperplastic islets and adenoma but was lost
in the invasive areas of grade 1 carcinoma and in all of grades 2 and
Fig. 2. In vivo bioluminescence of tumor growth over time. (A) Longitudinal analysis of luciferase bioluminescence in an individual RTL1 mouse over 4 weeks
shows increasing light emission over time. The same scale was used for all four images causing signal intensities out of scale at age 17 and 18.7 weeks
(white central area inside false colored area). Right panel: photon flow quantification of the (false) colored area in left panel. (B) Tumor growth in a cohort of
12 mice (average age at first monitoring: 15 weeks) was followed over 25 days by in vivo bioluminescence. The signal intensities were normalized for each mouse
individually, with 100% representing the geometrical mean of all values obtained per mouse during the 25 days observation period. Shown are means of the
12 mice ± SEMs.
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3 carcinoma (Figure 4B). Similar observations were made for insulin,
a characteristic b-cell marker. Lesions up to grade 1 retained insulin
expression, albeit at reduced levels compared with normal islets,
whereas grade 2 carcinoma eventually downregulated insulin expres-
sion in certain areas (Figure 4C). In order to determine major tran-
scriptional changes that could be involved in the differential
regulation of tumor onset and progression between RTL1 and Rip1-
Tag2 mice, we analyzed the expression of genes known to be critical
Fig. 3. Tumor progression in RTL1 mice. (A) Representative hematoxylin and eosin staining of histological sections from the various stages of tumor
development in RTL1 mice. (B) Disaggregated tumor cell clusters are found in hemorrhagic areas of RTL1 tumors. (C) In RTL1 mice, tumor cell clusters are found
in blood vessels within the exocrine pancreas as identified by the presence of erythrocytes and a clearly defined vascular lining. (D) Histological sections of
total pancreata of RTL1 and Rip1Tag2 mice stained with hematoxylin and eosin indicate that RTL1 mice have fewer lesions. Numbers indicate tumors.1 mm in
diameter within the sections. T: tumor, E: exocrine pancreas, LN: lymph node. Scale bars: (A–C): 50 lm and (D): 5 mm.
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Fig. 4. Analysis of tumor angiogenesis and tumor progression in RTL1 transgenic mice. (A) Immunofluorescent staining of RTL1 tumors with antibodies against
the endothelial marker CD31 (green) and the pericyte marker NG2 (red). The background observed in the red fluorescent channel originates from blood
hemorrhages. 4#,6-Diamidino-2-phenylindole (DAPI) visualizes nuclei (blue). (B) Fluorescent staining for E-cadherin (green) in an area of a grade 2 carcinoma
where E-cadherin has been lost in the invasive b tumor cells yet is maintained in non-invasive cells. DAPI visualizes nuclei (blue). (C) Immunohistochemical
staining of an RTL1 carcinoma with antibodies against insulin (brown). A partial downregulation of insulin expression is apparent in the dedifferentiated regions
of the tumor. (D and E) Gene expression analysis in macroscopic tumors of Rip1Tag2 and RTL1 mice by quantitative real-time PCR. (D) No significantly
different mRNA levels of the angiogenic factor VEGF-A or the transcriptional repressors E47, Snail1, Snail2 or ZEB2 were detected (N5 3–8 individual tumors
from each genotype). (E) Insulinomas upregulate IGF-II compared with islets but the receptor levels are unchanged (two individual islet isolations,
N 5 8 individual tumors for Rip1Tag2 and N 5 4 for RTL1). (F) Fluorescence-activated cell sorting analysis of immune cell infiltration into tumors of RTL1 or
Rip1Tag2 mice. P-values from unpaired two-tailed Student’s t-test. Shown are means ± SEMs. Scale bars: 50 lm.
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for tumor progression by quantitative PCR, including VEGF-A and
the major transcriptional repressors of E-cadherin gene expression,
Snail1, Snail2, Zeb1 and Zeb2 (Figure 4D). However, none of these
factors was differentially expressed between tumors of Rip1Tag2 and
RTL1 mice.
Previously, we have shown that IGF-II provides critical survival
signals for Rip1Tag2 tumorigenesis. Its expression correlates with
hyperproliferation, and growth of Rip1Tag2 tumors is severely im-
paired in IGF-II knockout mice (7). Similar to tumors in Rip1Tag2
mice, tumors in RTL1 mice showed very high expression of IGF-II as
compared with islets of Langerhans (Figure 4E). In contrast, expres-
sion of insulin receptor (InsR) and IGF1R, known receptors for
IGF-II, was unchanged between islets, Rip1Tag2 and RTL1 tumors
(Figure 4E). Together, these data indicate that tumor progression in
RTL1 mice is highly comparable with the multistage tumorigenesis
observed in Rip1Tag2 mice in various histopathological and molecu-
lar parameters.
Reduced infiltration by myeloid-derived suppressor cells
However, there are also significant differences between tumor devel-
opment in RTL1 and Rip1Tag2 mice. In addition to tumor cell-
intrinsic factors, it is now well established that myeloid cells can be
critical components in promoting tumor angiogenesis and metastasis
as well as in protection from adaptive immune responses (reviewed in
ref. 9). In particular, myeloid-derived suppressor cells (MDSC), char-
acterized by a concomitant expression of the myeloid marker CD11b
and the granulocyte marker Gr1, have been demonstrated to suppress
activation of dendritic and cytotoxic T cells, and their abundance
usually increases in peripheral blood and spleen with increasing tumor
size. By flow cytometry, we detected an increase in CD11bþ/Gr1þ
MDSC levels in peripheral blood and spleen of insulinoma-bearing
mice as compared with their non-tumor-bearing inbred strain. Nota-
bly, FVB/N mice have significantly less MDSC in peripheral blood
and spleen as compared with C57BL/6 mice, and consistent with this
notion, we found significantly less MDSC infiltrating the tumors of
RTL1 mice as compared with tumors from Rip1Tag2 mice (Figure 4F,
left panel), a difference that was also detected in spleen and peripheral
blood of tumor-bearing mice (Figure 4F, middle and right panels).
In order to assess early events that might explain the delayed
tumor progression in RTL1 mice as compared with Rip1Tag2 mice,
we analyzed the presence of tumor infiltrating lymphocytes in
8-week-old mice. Whereas no B lymphocyte infiltration was evident
(data not shown), T lymphocytes were present at comparable levels in
lesions of both strains (supplementary Figure S3B and C is available
at Carcinogenesis Online). In contrast, levels of infiltrating F4/80þ
macrophages were significantly reduced in RTL1 mice as compared
with Rip1Tag2 mice (supplementary Figure S3B and C is available at
Carcinogenesis Online). Signs of T lymphocytes attacking hyperplas-
tic islets, such as massive islet cell death or aggregates of T lympho-
cytes, were not apparent. In contrast, hyperplastic islets of RTL1 mice
showed a 3-fold decrease of the proliferation marker phospho-Histone
H3 as compared with Rip1Tag2 mice (supplementary Figure S3B and
C is available at Carcinogenesis Online), which could result from the
lower levels of T antigen expression in RTL1 mice (Figure 1C).
Lymph node and liver metastasis
Next, we assessed the metastatic dissemination of tumor cells and the
formation of metastasis in RTL1 mice. Histological analysis of pan-
creatic lymph nodes revealed lymph node metastases in 3 of 13 mice
with a total of 23 lymph nodes analyzed (Figure 5A). Since insulinoma
is known to metastasize to liver and lung both in man (29) and in mice
(30), the presence of tumor cells in these organs was analyzed in RTL1
single-transgenic mice by in vitro luciferase assays between 18 and
20 weeks of age. Luciferase activity was found increased at least 3-
fold above background in the livers of 19 of 66 mice (29%). Primary
tumor size significantly correlated with luciferase activity in liver
lysates (Figure 5B), and mice carrying primary tumors above a tumor
volume of 150 mm3 exhibited a 67% likelihood of liver metastasis
(Table I). The occurrence of liver metastasis was confirmed by the
presence of insulin-positive nodules in the liver (Figure 5C). Up to
20 of these insulin-positive structures were detectable in one histolog-
ical section of the livers of RTL1 mice, yet they never reached macro-
scopic size and remained below a diameter of 150 lm. Liver metastases
showed no hypoxia as analyzed by Ca-IX staining (data not shown)
and were also detected in RTL1;RipIGF1R, RTL1;NCAMþ/ and
RTL1;RipVEGF-C composite mice by in vitro luciferase assays of
organ lysates (Figure 5D and Table I) and by insulin staining of liver
sections (data not shown). RTL1;RipIGF1R double-transgenic mice
developed more metastasis than single-transgenic RTL1 mice.
The hepatic metastatic clusters in RTL1 mice were partially or com-
pletely surrounded by CD31- and lymphatic vessel endothelial hyalur-
onan receptor 1 (LYVE-1)-positive vessels (Figure 5E). In contrast to
many other organs in which LYVE-1 is a marker for lymphatic vessels
(31) or a subset of macrophages (32), hepatic sinusoidal endothelial
cells also express LYVE-1 (33). The blood endothelial character of the
vessels surrounding the metastatic nodules was further highlighted by
the erythrocytes present in the vessels (Figure 5C). Most metastatic
nodules were negative for the epithelial marker E-cadherin, which is
absent in most grade 2 primary carcinomas (Figure 5E). Yet, within
larger metastatic clusters, we found small patches of cells expressing
E-cadherin, indicating re-differentiation of metastatic cells. Immuno-
histochemical staining for phospho-Histone-3 revealed proliferating
cells within the metastatic nodules (Figure 5E).
Analysis of luciferase activities in lysates of various organs
from RTL1 mice revealed high levels in the lungs of 3 of 45 RTL1
mice, in 1 of 14 RTL1;RipVEGF-D mice and in 2 of 4 RTL1;
RipIGF1R mice, whereas in RTL1;RipVEGF-C, RTL1;RipVEGF-A
and RTL1;NCAMþ/ mice we did not detect any increased activities
in lung. In contrast to liver, we were not able to detect metastases by
histology in the contralateral lung lobe to the one used for ex vivo
luciferase analysis. In brain, we detected luciferase values above
background levels in only a few mice, and histological analysis of
brain sections also did not reveal any apparent micrometastasis.
Discussion
The Rip1Tag2 tumor model has proven to be extremely instructive in
identifying cellular processes and molecular pathways participating in
multistage tumorigenesis, including the molecular mechanisms un-
derlying the so-called angiogenic switch, tumor cell survival and
tumor invasion. Moreover, based on the high reproducibility of the
multiple stage of tumorigenesis in Rip1Tag2 transgenic mice, they
have also been frequently employed for preclinical testing of exper-
imental drugs. Yet, due to the location of insulinoma within the pan-
creas, Rip1Tag2 mice cannot be easily employed to monitor tumor
growth over time. Moreover, the incidental occurrence of metastatic
carcinoids sometimes complicates the evaluation of experiments and
may even obscure the interpretation of the results.
We here report on the generation and detailed characterization of an
improved version of the Rip1Tag2 tumor model. By the specific ex-
pression of a bicistronic mRNA coding for large T antigen and firefly
luciferase in b-cells of Langerhans islets, we have generated a trans-
genic mouse line (RTL1) that offers the possibility to monitor tumor
growth over time by bioluminescence analysis in vivo in a quantitative
manner. Although RTL1 mice frequently develop micrometastasis in
the regional lymph nodes and in the liver, they do not develop overt
macrometastasis before they succumb to hypoglycemia. Yet, the
micrometastasis can be detected and quantified with high sensitivity
by ex vivo/in vitro bioluminescence analysis of organ lysates. Com-
parison of histological analysis and ex vivo luciferase measurements
has yielded a detection threshold of 1 tumor cell in 100 000 target
organ cells. Thus, the low background of luminescence from normal
tissue, the rapid turnover of the luciferase enzyme and the non-
immunogenic characteristics of luciferin make this method ideally
suited for longitudinal in vivo imaging of tumor progression.
The rat insulin promoter has been used in numerous transgenic
mouse models to specifically target transgene expression to pancreatic
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b-cells. However, the onset of transgene expression can vary widely
between different founder lines. In RTL1 mice, T antigen mRNA and
luciferase protein are expressed in pancreas of newborns, suggesting
transgene expression onset before birth. The occurrence of hyperplas-
tic islets at 7 weeks of age also indicates early b-cell transformation,
yet the proliferation rate of hyperplastic islets is significantly lower in
RTL1 mice as compared with Rip1Tag2 mice. This could be due to
lower expression of T antigen in young RTL1 mice and is consistent
with the observed slow progression from hyperplastic islets to mac-
roscopic tumors. Indeed, a 5-day pulse of 5-bromodeoxyuridine
labeling of cells in S phase of the cell cycle has revealed
only 20% of BrdU-positive cells within RTL1 tumors (at 14 weeks)
compared with a 50% labeling efficiency in Rip1Tag2 mice at 8 weeks
of age (data not shown). However, faced by the fact that IGF-II,
VEGF-A and other growth parameters are comparably expressed in
the tumors of RTL1 and Rip1Tag2 mice, the difference between the
proliferative indices remains elusive and warrants further investigation.
The delay of tumor progression in RTL1 mice as compared
with Rip1Tag2 mice may also be due to significantly lower levels
of Gr1þ/CD11bþ MDSC in blood, spleen and tumors of RTL1
mice (in FVB/N background) as compared with Rip1Tag2 mice
(in C57BL/6 background). Besides repressing immunosurveillance,
MDSC and tumor-associated macrophages have been shown to sup-
port the angiogenic switch by providing MMP9 for the release of
Fig. 5. RTL1 tumors metastasize to the lymph node and liver. (A) RTL1 mice show lymph node metastasis in 3/13 mice (23%). Shown are a representative
hematoxylin and eosin staining (left panel) and an immunohistochemical insulin staining (right panel) of a histological section of a pancreatic lymph node of an
RTL1 mouse. (B) Metastatic dissemination of RTL1 tumors to liver correlates with primary tumor size. Normalized luciferase activity in liver homogenates
significantly correlates with primary tumor volume and is indicative of liver metastasis. The dashed line indicates the threshold defined as luciferase value
3-fold above background level (obtained with young RTL1 mice livers without primary tumors). (C) Histological analysis of liver metastasis in RTL1 mice.
Hematoxylin and eosin staining (left panel) and immunohistochemical staining for insulin (right panel) reveal metastatic nodules in livers of RTL1 mice.
The arrowhead indicates a blood vessel filled with erythrocytes (inset). (D) Composite mice also develop liver metastasis as determined by ex vivo/in vitro
luciferase analysis as described in panel (B). (E): Metastatic nodules in the liver are surrounded by sinusoidal endothelial venules as indicated by
immunofluorescence staining for LYVE-1 and CD31 (left panels). Most metastatic cells exhibit low or no E-cadherin expression, yet some cells (re)express this
epithelial marker (arrowhead, right top panel, inset). Staining for phospho-Histone-3 indicates cell proliferation within the metastatic nodule in the liver.
Scale bars: (A): 200 lm, (D) and (E): 50 lm.
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matrix-sequestered angiogenic factors, such as VEGF-A (6,34). It is
thus tempting to speculate that the reduced myeloid cell infiltration
into RTL1 tumors impairs tumor escape from immunosurveillance
and efficient tumor angiogenesis.
As frequently observed with malignant human insulinoma and
also in Rip1Tag2 mice (29,35,36), RTL1 mice develop liver metas-
tasis. The surrounding of metastatic nodules by LYVE-1þ sinusoidal
endothelial vessels and the absence of intrametastatic blood vessels
indicate that the metastatic nodules do not (yet) execute an angio-
genic program of their own to induce a functional intrametastatic
vasculature and thus metastatic outgrowth. However, 5% of cells
are positive for the mitosis marker phospho-Histone-3, demonstrat-
ing the proliferation capabilities of the metastatic nodules. The al-
most complete absence of E-cadherin in metastatic nodules suggests
that metastatic cells have undergone epithelial-to-mesenchymal
transition, a phenomenon often observed in cancers of epithelial
origin (37).
To directly compare the signaling pathways and mechanistic pro-
cesses required for b-cell tumorigenesis in RTL1 and Rip1Tag2
mice, we have crossed RTL1 mice to a variety of transgenic mice
expressing ‘tumor modifiers’ in b tumor cells and that have been
previously crossed to Rip1Tag2 mice. All composite RTL1 trans-
genic mice analyzed show phenotypes highly comparable with
the composite mice described for Rip1Tag2. For example,
RTL1;RipIGF1R mice show massively accelerated tumor progres-
sion. Also expected, RTL1;RipVEGF-C and RTL1;RipVEGF-D
exhibit increased peritumoral lymphangiogenesis, rarely detected
in RTL1 single-transgenic mice (data not shown). However, in
contrast to the occurrence of lung metastases in 80% of
Rip1Tag2;RipVEGF-D mice (23), only one 1 of 14 RTL1;RipVEGF-
D mice has developed lung metastasis. Also in contrast to Rip1Tag2
mice, in RTL1 mice, the transgenic expression of VEGF-D does not
trigger massive lymphocyte infiltration, an inflammatory stimulus that
potentially supports metastatic events (38).
In conclusion, the RTL1 mouse model of pancreatic b-cell car-
cinogenesis is a valuable tool to monitor primary tumor growth and
metastasis formation in a non-invasive manner and in a longitudinal
axis. Based on its high reproducibility in multistage tumor pro-
gression and the possibility to modulate tumor progression by
pharmacological and genetic means, the RTL1 mouse model offers
the opportunity to test innovative therapeutic approaches at a
preclinical level. Finally, RTL1 transgenic mice can be easily
employed to delineate the functional contribution of genes of
interest to tumor progression and metastasis by genetic for proof-
of-principle experimentation.
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Supplementary Methods, Tables S1 and S2, Figures S1–S3 and
Figures 1 and 2 can be found at http://carcin.oxfordjournals.org/
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